missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CTS™ CytoTune™-iPS 2.1 Sendai Reprogramming Kit
The first off-the-shelf reprogramming system designed for clinical and translational research
Brand: Invitrogen™ A34546
This item is not returnable.
View return policy
Description
The CTS™ CytoTune™-iPS 2.1 Sendai Reprogramming Kit is the first off-the-shelf reprogramming system designed for clinical and translational research. Like the CytoTune-iPS 2.0 Sendai reprogramming kit, this kit uses Sendai particles to deliver Yamanaka factors that are critical for efficient generation of induced pluripotent stem cells (iPSCs). This kit includes three vector preparations: polycistronic Klf4–Oct3/4–Sox2 (KOS), L-Myc, and Klf4.
Manufactured in accordance with GMP requirements:
This product is manufactured at a site with an ISO9001-certified quality management system. The facility and process were audited for conformity with current Good Manufacturing Practices for medical devices, 21 CFR Part 820 of the regulation.
Formulated animal origin–free:
The bovine serum albumin carrier protein was removed from the CTS CytoTune-iPS 2.1 Sendai vector formulation. The preparation contains no animal-derived components at the primary component level.
Accompanied by documentation to support your regulatory filing:
Full traceability documentation such as Certificate of Origin and Certificate of Analysis are available.
What you get:
The kit includes 0.2 mL of each vector (KOS, Klf4, and L-myc) at a titer of 0.5–2.0 x 108 CFU/mL, sufficient to reprogram a minimum of six wells of a six-well plate.
Specifications
| • 0.2 mL CTS CytoTune KOS • 0.2 mL CTS CytoTune Klf4 • 0.2 mL CTS CytoTune L-myc Store at -70°C. |
|
| Cell and Gene Therapy Research, Development, and Manufacturing | |
| iPSC Reprogramming Kit | |
| Dry Ice |
| Sendai | |
| CTS™ | |
| 1 kit |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction